All In Biotech

Drug Trial Radar · NCT07703683

Myokines as Potential Biomarkers and Drivers of Sarcopenia in Metabolic and Endocrine Diseases

Last checked: Nov 20, 2026Latest source record: Jul 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

100

Planned (sponsor's estimate)

Start

Feb 19, 2026

Primary completion

Dec 31, 2056

Study completion Dec 31, 2056

Sponsor

Sponsor type
Academic, hospital or other
First posted
Jul 14, 2026

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Prospective, observational, single-center, study evaluating the prevalence of sarcopenia / sarcopenic obesity in individuals with metabolic and / or endocrine diseases, as well as the potential role of myokines as biomarkers or drivers of sarcopenia / sarcopenic obesity in this population. .

Conditions

  • Diabetes
  • Obesity & Overweight
  • Cushing Syndrome
  • Metabolic Diseases
  • Endocrine Diseases
  • Sarcopenia
  • Sarcopenic Obesity

Interventions

  • GLP-1 Receptor AgonistsDrug

    Participants receive GLP-1 RA or GLP-1/GIP dual agonists as part of their standard care for overweight or obesity

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Prevalence of sarcopenia / sarcopenic obesityTime frame: From February 2026 to december 2056

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Cliniques Universitaires Saint-Luc

    Woluwe-Saint-Pierre - Sint-Pieters-Woluwe, Belgium · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.